SYNALAR (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 1963.
Drug data last refreshed 13h ago · AI intelligence enriched 19h ago
SYNALAR (fluocinolone acetonide) is a potent topical corticosteroid ointment that acts as a corticosteroid hormone receptor agonist. It is indicated for inflammatory and pruritic dermatological conditions, working by suppressing local immune and inflammatory responses in the skin.
As LOE approaches, the brand team is likely consolidating around retention strategies and generic transition planning, with reduced headcount expected post-loss of exclusivity.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Worked on SYNALAR at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SYNALAR offers limited career growth due to its LOE-approaching status and minimal linked job openings. Professionals on this brand should anticipate transition planning and may benefit from exploring adjacent product portfolios or leveraging generic market expertise.